Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension

被引：1
|
作者：
Tocci, Giuliano [1 ,2 ]
机构：
[1] Univ Rome Sapienza, Dept Clin & Mol Med, St Andrea Hosp, Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
来源：
CARDIOLOGY | 2020年 / 145卷 / 09期
关键词：
ANGIOTENSIN-II RECEPTOR; NEPRILYSIN; GUIDELINES; ALISKIREN; INHIBITOR;
D O I：
10.1159/000508345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of sacubitril/valsartan (LCZ696) in reducing adverse cardiovascular events and controlling hypertension among asians: a meta-analysis of randomised controlled trials
    Cruz, P. Vera
    Ang, W.
    Calatrava, J. B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 251 - 251
  • [32] LCZ696, The Need for an Indication in Arterial Hypertension
    Prado, Jose C.
    Ruilope, Luis M.
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (12) : 1403 - 1404
  • [33] Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension
    Hsiao, H-L
    Langenickel, T. H.
    Petruck, J.
    Kode, K.
    Ayalasomayajula, S.
    Schuehly, U.
    Greeley, M.
    Pal, P.
    Zhou, W.
    Prescott, M. F.
    Sunkara, G.
    Rajman, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (03) : 468 - 476
  • [34] Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study
    Shi, Victor
    Senni, Michele
    Streefkerk, Hendrik
    Modgill, Vikas
    Zhou, Wenchun
    Kaplan, Allen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 264 : 118 - 123
  • [35] Efficacy and Safety of LCZ696 Compared with Olmesartan in Japanese Patients with Systolic Hypertension
    Rakugi, Hiromi
    Kario, Kazuomi
    Yamaguchi, Masako
    Okino, Naoko
    Gotou, Hiromi
    Zhang, Jack
    HYPERTENSION, 2014, 64
  • [36] Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
    Mochel, Jonathan P.
    Teng, Chi Hse
    Peyrou, Mathieu
    Giraudel, Jerome
    Danhof, Meindert
    Rigel, Dean F.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 : 103 - 111
  • [37] The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway
    Gundersen, V.
    Eklund, O.
    Hancock, E.
    Hussain, R.
    Ohna, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 203 - 203
  • [38] Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects
    Yi Han
    Surya Ayalasomayajula
    Wei Pan
    Fan Yang
    Yaozong Yuan
    Thomas Langenickel
    Markus Hinder
    Sampath Kalluri
    Parasar Pal
    Gangadhar Sunkara
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 109 - 116
  • [39] Effect of food on the oral bioavailability of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
    Ayalasomayajula, Surya
    Langenickel, Thomas H.
    Chandra, Priya
    Wolfson, Edward D.
    Albrecht, Diego
    Zhou, Wel
    Pal, Parasar
    Rajman, Iris
    Sunkara, Gangadhar
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (12) : 1012 - 1018
  • [40] Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects
    Han, Yi
    Ayalasomayajula, Surya
    Pan, Wei
    Yang, Fan
    Yuan, Yaozong
    Langenickel, Thomas
    Hinder, Markus
    Kalluri, Sampath
    Pal, Parasar
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (01) : 109 - 116
12345